DIGRE: Drug-Induced genomic residual effect model for successful prediction of multidrug effects

J. Yang, H. Tang, Y. Li, R. Zhong, T. Wang, S. T C Wong, G. Xiao, Y. Xie

Research output: Contribution to journalArticle

Abstract

Multidrug regimens are a promising strategy for improving therapeutic efficacy and reducing side effects, especially for complex disorders such as cancer. However, the use of multidrug therapies is very challenging, due to a lack of understanding of the mechanisms of drug interactions. We herein present a novel computational approach-Drug-Induced Genomic Residual Effect (DIGRE) Computational Model-to predict drug combination effects by explicitly modeling drug response curves and gene expression changes after drug treatments. The prediction performance of DIGRE was evaluated using two datasets: (i) OCI-LY3 B-Lymphoma cells treated with 14 different drugs and (ii) MCF breast cancer cells treated with combinations of gefitinib and docetaxel at different doses. In both datasets, the predicted drug combination effects significantly correlated with the experimental results. The results indicated the model was useful in predicting drug combination effects, which may greatly facilitate the discovery of new, effective multidrug therapies.

Original languageEnglish (US)
Article numbere200
JournalCPT: Pharmacometrics and Systems Pharmacology
Volume3
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Genomics
Drugs
Drug Combinations
Drug interactions
Drug therapy
Prediction
docetaxel
Gene expression
Pharmaceutical Preparations
Cells
Drug Design
B-Cell Lymphoma
Drug Interactions
Model
Therapy
Therapeutics
Breast Neoplasms
Gene Expression
Cell
Performance Prediction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

DIGRE : Drug-Induced genomic residual effect model for successful prediction of multidrug effects. / Yang, J.; Tang, H.; Li, Y.; Zhong, R.; Wang, T.; Wong, S. T C; Xiao, G.; Xie, Y.

In: CPT: Pharmacometrics and Systems Pharmacology, Vol. 3, No. 7, e200, 2014.

Research output: Contribution to journalArticle

@article{17f9e68fd6df48aa98eaa031e17b7019,
title = "DIGRE: Drug-Induced genomic residual effect model for successful prediction of multidrug effects",
abstract = "Multidrug regimens are a promising strategy for improving therapeutic efficacy and reducing side effects, especially for complex disorders such as cancer. However, the use of multidrug therapies is very challenging, due to a lack of understanding of the mechanisms of drug interactions. We herein present a novel computational approach-Drug-Induced Genomic Residual Effect (DIGRE) Computational Model-to predict drug combination effects by explicitly modeling drug response curves and gene expression changes after drug treatments. The prediction performance of DIGRE was evaluated using two datasets: (i) OCI-LY3 B-Lymphoma cells treated with 14 different drugs and (ii) MCF breast cancer cells treated with combinations of gefitinib and docetaxel at different doses. In both datasets, the predicted drug combination effects significantly correlated with the experimental results. The results indicated the model was useful in predicting drug combination effects, which may greatly facilitate the discovery of new, effective multidrug therapies.",
author = "J. Yang and H. Tang and Y. Li and R. Zhong and T. Wang and Wong, {S. T C} and G. Xiao and Y. Xie",
year = "2014",
doi = "10.1038/psp.2014.8",
language = "English (US)",
volume = "3",
journal = "CPT: Pharmacometrics and Systems Pharmacology",
issn = "2163-8306",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - DIGRE

T2 - Drug-Induced genomic residual effect model for successful prediction of multidrug effects

AU - Yang, J.

AU - Tang, H.

AU - Li, Y.

AU - Zhong, R.

AU - Wang, T.

AU - Wong, S. T C

AU - Xiao, G.

AU - Xie, Y.

PY - 2014

Y1 - 2014

N2 - Multidrug regimens are a promising strategy for improving therapeutic efficacy and reducing side effects, especially for complex disorders such as cancer. However, the use of multidrug therapies is very challenging, due to a lack of understanding of the mechanisms of drug interactions. We herein present a novel computational approach-Drug-Induced Genomic Residual Effect (DIGRE) Computational Model-to predict drug combination effects by explicitly modeling drug response curves and gene expression changes after drug treatments. The prediction performance of DIGRE was evaluated using two datasets: (i) OCI-LY3 B-Lymphoma cells treated with 14 different drugs and (ii) MCF breast cancer cells treated with combinations of gefitinib and docetaxel at different doses. In both datasets, the predicted drug combination effects significantly correlated with the experimental results. The results indicated the model was useful in predicting drug combination effects, which may greatly facilitate the discovery of new, effective multidrug therapies.

AB - Multidrug regimens are a promising strategy for improving therapeutic efficacy and reducing side effects, especially for complex disorders such as cancer. However, the use of multidrug therapies is very challenging, due to a lack of understanding of the mechanisms of drug interactions. We herein present a novel computational approach-Drug-Induced Genomic Residual Effect (DIGRE) Computational Model-to predict drug combination effects by explicitly modeling drug response curves and gene expression changes after drug treatments. The prediction performance of DIGRE was evaluated using two datasets: (i) OCI-LY3 B-Lymphoma cells treated with 14 different drugs and (ii) MCF breast cancer cells treated with combinations of gefitinib and docetaxel at different doses. In both datasets, the predicted drug combination effects significantly correlated with the experimental results. The results indicated the model was useful in predicting drug combination effects, which may greatly facilitate the discovery of new, effective multidrug therapies.

UR - http://www.scopus.com/inward/record.url?scp=84905406860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905406860&partnerID=8YFLogxK

U2 - 10.1038/psp.2014.8

DO - 10.1038/psp.2014.8

M3 - Article

AN - SCOPUS:84905406860

VL - 3

JO - CPT: Pharmacometrics and Systems Pharmacology

JF - CPT: Pharmacometrics and Systems Pharmacology

SN - 2163-8306

IS - 7

M1 - e200

ER -